This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.
lower gastrointestinal tract motility regulators
Acts as a spasmolytic.
Absorption: Rapidly absorbed following oral administration.
Metabolism and Excretion: Extensively metabolized, <2.4% excreted unchanged in urine.
Half-life: 2.7–3.1 hr.
TIME/ACTION PROFILE (symptom relief)
|PO||within 3 days–2 wk||1 hr (blood level)||>1 wk (following discontuation)|
Use Cautiously in:
CNS: dizziness, drowsiness, fatigue, headache
GI: diarrhea, dry mouth, dysguesia, dyspepsia, epigastric pain, nausea
Derm: hot/cold sensation, rash
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
PO (Adults) 200 mg 3 times daily.
Tablets: 100 mg, 200 mg
Decrease signs and symptoms of irritable bowel disease.
Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Complete Product Information.